Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

European pharmaceutical giant Novo Nordisk (NVO) has struck a licensing deal with U.S. biotech firm Septerna (SEPN) to ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...